Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ATOS by emailGet an email when ATOS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ATOS, unsubscribe in one click. Privacy
📣 What ATOS Says Is Next
late 2026 · “With this data, we plan to cultivate meaningful partnership opportunities for (Z)-endoxifen as a combination therapy with existing partners (Lilly and AbbVie) as well as potential new partner candidates. b) EVANGELINE: Complete Enrollment and Data Generation with the Mayo Clinic Enrollment in the EVANGELINE study will conclude by mid-year with preliminary data becoming available in late 2026. (Atossa Therapeutics Investors) 3.”
Company press release, Feb 11, 2026 · SEC filing
second half of 2026 · “Enrollment under the combination therapy arms of this trial involving (Z)-endoxifen with abemaciclib, and in some cases additional ovarian function suppression treatment, is nearly complete, and we expect data to be available during the second half of 2026.”
Company press release, Feb 11, 2026 · SEC filing
in 2026 · “The Company also anticipates additional IND submissions in 2026 to advance combination strategies and explore opportunities beyond monotherapy and breast cancer.”
Company press release, Dec 4, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ATOS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATOS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.